SCHEMBL6161952

SCHEMBL6161952

O/N=C(\CBr)c1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 3/20 0.48
PTPN1 P18031 2/20 0.48
ATM Q13315 1/20 0.46
CES1 P23141 2/20 0.42
CES2 O00748 1/20 0.42
ALDH1A1 P00352 2/20 0.40
HTT P42858 1/20 0.40
TRPA1 O75762 1/20 0.40
TSHR P16473 1/20 0.40
GAA P10253 3/20 0.39
CYP2C19 P33261 1/20 0.39
DRD4 P21917 2/20 0.38
CA12 O43570 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
CA9 Q16790 1/20 0.38
TDP1 Q9NUW8 2/20 0.37
HDAC8 Q9BY41 1/20 0.37
HPGD P15428 2/20 0.36
MEN1 O00255 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22024926 1.00 GSK3B (0.48) GSK3BPTPN1ATMCES1CES2
SCHEMBL3891431 1.00 GSK3B (0.48) GSK3BPTPN1ATMCES1CES2
Water SCHEMBL11163579 0.98 GSK3B (0.46) GSK3BPTPN1ATMCES1CES2
SCHEMBL2470468 0.78 ATM (0.48) ATMCES1CES2ALDH1A1HTT
SCHEMBL8388578 0.77 GSK3B (0.52) GSK3BATMCES1CES2ALDH1A1
SCHEMBL11093317 0.77 GSK3B (0.52) GSK3BATMCES1CES2ALDH1A1
SCHEMBL11093321 0.77 GSK3B (0.52) GSK3BATMCES1CES2ALDH1A1
SCHEMBL28761026 0.77 PTPN1 (0.52) GSK3BPTPN1CES1CES2ALDH1A1
SCHEMBL6630645 0.76 ATM (0.46) ATMCES1ALDH1A1HTTGAA
SCHEMBL9834835 0.76 ATM (0.46) ATMHTTGAACYP2C19DRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9326930-B2 Calcium sequestration compositions and methods of treating skin pigmentation disorders and conditions NEOCUTIS S.A. (CH) 2016-05-03 US disclosed
US-9326930-B2 Calcium sequestration compositions and methods of treating skin pigmentation disorders and conditions NEOCUTIS S.A. (CH) 2016-05-03 US disclosed
US-9326930-B2 Calcium sequestration compositions and methods of treating skin pigmentation disorders and conditions NEOCUTIS S.A. (CH) 2016-05-03 US disclosed
US-20160030321-A1 CALCIUM SEQUESTRATION COMPOSITIONS AND METHODS OF TREATING SKIN PIGMENTATION DISORDERS AND CONDITIONS NEOCUITIS S A (CH) 2016-02-04 US disclosed
US-20160030321-A1 CALCIUM SEQUESTRATION COMPOSITIONS AND METHODS OF TREATING SKIN PIGMENTATION DISORDERS AND CONDITIONS NEOCUITIS S A (CH) 2016-02-04 US disclosed
US-20160030321-A1 CALCIUM SEQUESTRATION COMPOSITIONS AND METHODS OF TREATING SKIN PIGMENTATION DISORDERS AND CONDITIONS NEOCUITIS S A (CH) 2016-02-04 US disclosed
US-20140057334-A1 AGENT THAT MODULATES PHYSIOLOGICAL CONDITION OF PESTS, INVOLVED IN INSECT CHOLINE ACETYLTRANSFERASE ACTIVITY SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2014-02-27 US disclosed
US-20140057334-A1 AGENT THAT MODULATES PHYSIOLOGICAL CONDITION OF PESTS, INVOLVED IN INSECT CHOLINE ACETYLTRANSFERASE ACTIVITY SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2014-02-27 US disclosed
US-8476035-B2 Agent that modulates physiological condition of pests, involved in insect choline acetyltransferase activity SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2013-07-02 US disclosed
US-8476035-B2 Agent that modulates physiological condition of pests, involved in insect choline acetyltransferase activity SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2013-07-02 US disclosed
US-20110028423-A1 AGENT THAT MODULATES PHYSIOLOGICAL CONDITION OF PESTS, INVOLVED IN INSECT CHOLINE ACETYLTRANSFERASE ACTIVITY SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-02-03 US disclosed
US-20110028423-A1 AGENT THAT MODULATES PHYSIOLOGICAL CONDITION OF PESTS, INVOLVED IN INSECT CHOLINE ACETYLTRANSFERASE ACTIVITY SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-02-03 US disclosed
EP-0755923-B1 Ameliorant or remedy for symptoms caused by Ischemic diseases and Phenylpiperidine compounds useful therefor DAIICHI SUNTORY PHARMA CO LTD (JP) 2005-05-04 EP disclosed
US-6469010-B1 COMPOSITION ALSO FOR ALLEVIATION OR TREATMENT OF SYMPTOMS DERIVED FROM SEIZURES, EPILEPSY AND MIGRAINE HEADACHES, AND SUPPRESSION OF CALCIUM ION OVERLOAD SUNTORY LIMITED (JP) 2002-10-22 US disclosed
US-6048876-A ANTICONVULSANTS; ANTIEPILEPIC AGENT SUNTORY LIMITED (JP) 2000-04-11 US disclosed
EP-0755923-A1 AMELIORANT OR REMEDY FOR SYMPTOMS CAUSED BY ISCHEMIC DISEASES AND COMPOUNDS USEFUL THEREFOR SUNTORY LIMITED (JP) 1997-01-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160030321-A1 CALCIUM SEQUESTRATION COMPOSITIONS AND METHODS OF TREATING SKIN PIGMENTATION DISORDERS AND CONDITIONS S100A4, TYR, CACYBP GSK3B 1116/4885PTPN1 2741/4885ATM 4212/4885
US-20110028423-A1 AGENT THAT MODULATES PHYSIOLOGICAL CONDITION OF PESTS, INVOLVED IN INSECT CHOLINE ACETYLTRANSFERASE ACTIVITY ACHE, CHAT, BCHE GSK3B 4014/4885PTPN1 4070/4885ATM 2262/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.